Published

Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Unknown
Date: 2025-08-14
Source: Europe PMC
DOI: 10.1016/j.psychres.2025.116697
PubMed: 40840197

Authors

Rosa I Padula LP Semeraro F Marrangone C Inserra A De Risio L Boffa M Zoratto F Borgi M Guidotti R Lorenzo GD D'Addario C Pettorruso M Martinotti G.

Watch author

Derived topics and classifications

psilocybin Depression Mechanism of Action Receptor Pharmacology Review Article Animal Study Treatment-Resistant Depression Review Article

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Psychedelics and mental health: reimagining care through science, insight, and compassionFrontiers in Pharmacology · 2025-09-02 Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders?Research Directions Depression · 2023-10-12 Psilocybin to Manage Cancer-Related DepressionUnknown journal · 2016-12-20 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-18 Psilocybin may help cancer patients with depression and anxiety for yearsAccess Science · 2019-12-31 The Utility of Psilocybin in Managing Anxiety and Depression in Cancer PatientsBiochemistry and Molecular Biology Education · 2018-07-31 Can Psilocybin Treat Severe DepressionJournal watch · 2017-11-02